Meeting
2011 ASCO Annual Meeting
Hormone therapy versus chemotherapy as first-line treatment for estrogen receptor-positive metastatic breast cancer (MBC) patients.
Authors
T. Y. Chang
National Taiwan University Hospital, Taipei, Taiwan
T. Y. Chang , C. Lin , Y. Lu , S. H. Kuo , S. Huang , C. Huang , A. Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 29: 2011 (suppl; abstr 622)
Abstract #
622
Poster Bd #
11H
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).
First Author: Kyung Hae Jung
Poster
2020 ASCO Virtual Scientific Program
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
First Author: Matthew Loft
Poster
2019 ASCO Annual Meeting
Germline BRCA1and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry.
First Author: Peter A. Fasching
Poster
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
First Author: Mark Danese